LTRN

Lantern Pharma Inc

LTRN, USA

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

https://www.lanternpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LTRN
stock
LTRN

Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? Defense World

Read more →
LTRN
stock
LTRN

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Pensacola News Journal

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$22

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.74

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-43.57 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-30.66 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.42

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 25.65% of the total shares of Lantern Pharma Inc

1.

BIOS CAPITAL MANAGEMENT, LP

(9.9631%)

since

2025/06/30

2.

Vanguard Group Inc

(3.368%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.3208%)

since

2025/07/31

4.

CM Management, LLC

(1.852%)

since

2025/06/30

5.

Geode Capital Management, LLC

(0.8509%)

since

2025/06/30

6.

Renaissance Technologies Corp

(0.8389%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6324%)

since

2025/07/31

8.

Goss Wealth Management LLC

(0.5232%)

since

2025/06/30

9.

Voss Capital LLC

(0.463%)

since

2025/06/30

10.

Fidelity Extended Market Index

(0.398%)

since

2025/07/31

11.

BlackRock Inc

(0.3915%)

since

2025/06/30

12.

Dimensional Fund Advisors, Inc.

(0.3791%)

since

2025/06/30

13.

Westside Investment Management, Inc.

(0.3324%)

since

2025/06/30

14.

Horizon Kinetics Medical ETF

(0.2666%)

since

2025/08/29

15.

Horizon Asset Management Inc/ny

(0.2554%)

since

2025/06/30

16.

Bank of New York Mellon Corp

(0.2452%)

since

2025/06/30

17.

Davenport & Company LLC

(0.239%)

since

2025/06/30

18.

UBS Group AG

(0.2283%)

since

2025/06/30

19.

State Street Corp

(0.219%)

since

2025/06/30

20.

DFA US Targeted Value I

(0.2004%)

since

2025/07/31

21.

Commonwealth Equity Services Inc

(0.1682%)

since

2025/06/30

22.

iShares Micro-Cap ETF

(0.1653%)

since

2025/08/31

23.

Northern Trust Corp

(0.1444%)

since

2025/06/30

24.

Fidelity Total Market Index

(0.1423%)

since

2025/07/31

25.

Extended Equity Market Fund K

(0.1398%)

since

2025/06/30

26.

XTX Topco Ltd

(0.1169%)

since

2025/06/30

27.

Fidelity Series Total Market Index

(0.1107%)

since

2025/07/31

28.

Spartan Extended Market Index Pool F

(0.097%)

since

2025/07/31

29.

Northern Trust Extended Eq Market Idx

(0.0799%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - L

(0.0799%)

since

2025/06/30

31.

Fidelity Nasdaq Composite Index

(0.0633%)

since

2025/07/31

32.

NT Ext Equity Mkt Idx Fd - NL

(0.06%)

since

2025/06/30

33.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0554%)

since

2024/12/31

34.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0466%)

since

2025/06/30

35.

Wells Fargo & Co

(0.0462%)

since

2025/06/30

36.

Spartan Total Market Index Pool G

(0.0422%)

since

2025/07/31

37.

Dimensional US Targeted Value ETF

(0.0343%)

since

2025/08/29

38.

DFA US Vector Equity Class F

(0.032%)

since

2025/06/30

39.

Group One Trading, LP

(0.0275%)

since

2025/06/30

40.

DFA US Core Equity 2 I

(0.026%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.39

EPS Estimate

-0.44

EPS Difference

0.05

Surprise Percent

11.3636%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.